{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T05:27:06Z","timestamp":1735968426234,"version":"3.32.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In prolactinoma diagnosis, current guidelines recommend prolactin (PRL) assessment, considering values exceeding 200\u2005ng\/mL highly suggestive of prolactinoma. However, subtler hyperprolactinemia is more common, and to rule out potential prolactinomas, pituitary resonance magnetic imaging (MRI) studies are necessary. These present limitations in terms of availability, costs, and delays in diagnosis. We aimed to evaluate the screening utility of the metoclopramide (MCP) test in identifying patients with moderate hyperprolactinemia for whom MRI studies might be unnecessary.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively selected patients with moderate hyperprolactinemia, with an MCP test and a pituitary MRI within the same assistance, and with no interfering pharmacological treatment. Increases in PRL (\u0394PRLMax) and thyrotropin (\u0394TSHMax) after MCP infusion were compared according to MRI findings: patients with microadenoma (&amp;lt;10\u2005mm; n = 23), with macroadenoma (\u226510\u2005mm; n = 5), or without adenoma (n = 39).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\u0394PRLMax exceeds baseline PRL capability to identify patients with an adenoma (area under the curve = 0.872 vs 0.776). \u0394PRLMax below 220% identifies 100% of these patients with 71% of specificity. This screening would have avoided 42% of MRI, resulting in a cost savings of 34%. Analysis of \u0394TSHMax only slightly increased specificity when considered as a secondary criterion. Test duration can be shortened to 30\u2005min without compromising its screening capability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A short MCP test is a useful and cost-effective screening tool to avoid unnecessary MRI. Its simplicity allows its performance in almost any clinical facility to easily rule out prolactinoma in an important percentage of patients, something of upmost importance especially in regions where MRI facilities or their access are limited.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jalm\/jfae123","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:50:03Z","timestamp":1735897803000},"page":"48-58","source":"Crossref","is-referenced-by-count":0,"title":["Screening with Metoclopramide Test to Reduce Unnecessary Pituitary Magnetic Resonance Studies in Moderate Hyperprolactinemia"],"prefix":"10.1093","volume":"10","author":[{"given":"Ana","family":"Moreno","sequence":"first","affiliation":[{"name":"Service of Biochemistry, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Deza","sequence":"additional","affiliation":[{"name":"Service of Biochemistry, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Salvador","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C","family":"Galofre","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"IdiSNA, Navarra Institute for Health Research \u00a0 Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-273X","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Service of Biochemistry, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"IdiSNA, Navarra Institute for Health Research \u00a0 Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9053-3606","authenticated-orcid":false,"given":"Estibaliz","family":"Alegre","sequence":"additional","affiliation":[{"name":"Service of Biochemistry, Cl\u00ednica Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"IdiSNA, Navarra Institute for Health Research \u00a0 Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"2025010309490385000_jfae123-B1","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"2025010309490385000_jfae123-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000499694","article-title":"Pitfalls in the diagnostic evaluation of hyperprolactinemia","volume":"109","author":"Vilar","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2025010309490385000_jfae123-B3","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2025010309490385000_jfae123-B4","first-page":"63","article-title":"Macroprolactin: from laboratory to clinical practice","volume":"69","author":"Biagetti","year":"2022","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"2025010309490385000_jfae123-B5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an Endocrine Society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025010309490385000_jfae123-B6","doi-asserted-by":"crossref","first-page":"g5390","DOI":"10.1136\/bmj.g5390","article-title":"Diagnosis and management of prolactinomas and non-functioning pituitary adenomas","volume":"349","author":"Rogers","year":"2014","journal-title":"BMJ"},{"key":"2025010309490385000_jfae123-B7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2265.1983.tb03191.x","article-title":"Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia","volume":"18","author":"Massara","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025010309490385000_jfae123-B8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2265.1997.1350956.x","article-title":"An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia","volume":"46","author":"Sawers","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025010309490385000_jfae123-B9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0026-0495(85)90138-6","article-title":"Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients","volume":"34","author":"De Marinis","year":"1985","journal-title":"Metabolism"},{"key":"2025010309490385000_jfae123-B10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2265.1981.tb00608.x","article-title":"Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function","volume":"14","author":"Scanlon","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025010309490385000_jfae123-B11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/med\/9780199235292.003.2122","volume-title":"Oxford textbook of endocrinology and diabetes","author":"Bevan","year":"2011","edition":"2nd Ed"},{"key":"2025010309490385000_jfae123-B12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025010309490385000_jfae123-B13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2025010309490385000_jfae123-B14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025010309490385000_jfae123-B15","doi-asserted-by":"crossref","first-page":"832361","DOI":"10.3389\/fendo.2022.832361","article-title":"Metoclopramide test in hyperprolactinemic women with polycystic ovarian syndrome: old wine into new bottles?","volume":"13","author":"Rodier","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025010309490385000_jfae123-B16","volume-title":"Tarifas para facturaci\u00f3n de servivios sanitarios y docentes de osakidetza para el a\u00f1o 2024","author":"Osakidetza","year":"2023"},{"key":"2025010309490385000_jfae123-B17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00266-010-9595-6","article-title":"Galactorrhea after aesthetic breast augmentation with silicone implants: report of two cases and management of postoperative galactorrhea","volume":"35","author":"Ayestaray","year":"2011","journal-title":"Aesthetic Plast Surg"},{"key":"2025010309490385000_jfae123-B18","first-page":"267","article-title":"Hyperprolactinemia and mammary prostheses. A report of eight cases","volume":"31","author":"Ruiz-Velasco","year":"1986","journal-title":"J Reprod Med"},{"key":"2025010309490385000_jfae123-B19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/09513599609041264","article-title":"No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration","volume":"10","author":"Maraschini","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"2025010309490385000_jfae123-B20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2265.1992.tb02900.x","article-title":"Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests","volume":"36","author":"Webster","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025010309490385000_jfae123-B21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ando.2007.03.013","article-title":"Etiological diagnosis of hyperprolactinemia","volume":"68","author":"Cortet-Rudelli","year":"2007","journal-title":"Ann Endocrinol (Paris)"},{"key":"2025010309490385000_jfae123-B22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/09513590.2016.1222363","article-title":"Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia","volume":"33","author":"Espinos","year":"2017","journal-title":"Gynecol Endocrinol"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/1\/48\/61265866\/jfae123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/1\/48\/61265866\/jfae123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:50:11Z","timestamp":1735897811000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/1\/48\/7931440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfae123","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}